GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apremilast overview

Apremilast (Otezla) is a musculoskeletal system agent. It is formulated as a film-coated tablets, tablets for oral route of administration. Otezla is indicated for the treatment of adult patients with active psoriatic arthritis. It is also indicated in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Otezla used alone or in combination with disease-modifying antirheumatic drugs for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or were an intolerant to previous DMARD therapy and in pediatric patients, indicated for the treatment of chronic plaque psoriasis moderate to severe in adult patients who have not responded, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet type A PUVA), and for the treatment of adult and pediatric patients with oral ulcers associated with Behçet’s Disease.

It is under development for the treatment of atopic dermatitis (atopic eczema), plaque psoriasis (psoriasis vulgaris), psoriatic arthritis, bullous pemphigoid and behcet disease.

It was also under development for gouty arthritis, discoid lupus erythematosus (DLE), sarcoidosis, genito urinary system and sex hormones, rosacea, osteoarthritis, crohn's disease, rheumatoid arthritis, asthma, pruritus, ankylosing spondylitis, ulcerative colitis, canker sores, covid-19, acne vulgaris and erosive oral lichen planus, prurigo, hidradenitis suppurativa, vitiligo.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.

For a complete picture of Apremilast’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.